Supplement
Vitamin K (MK-7)
SaveVitamin K2 (menaquinone-7) is the preferred supplemental form for bone and cardiovascular health, activating osteocalcin and matrix Gla protein to direct calcium appropriately.
Quick verdict
Strong rationale and growing evidence for bone density and arterial calcification prevention. Important companion to vitamin D3 supplementation.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
MK-7 has the longest half-life among K2 forms (~72 hours). Clinical trials show improved bone mineral density and reduced fracture risk in some populations. Observational data links K2 intake to reduced cardiovascular calcification.
Benefits
- Activates osteocalcin for bone mineralization
- Activates matrix Gla protein to prevent vascular calcification
- Long half-life allows once-daily dosing
- Synergistic with vitamin D3
Dosage notes
100–200 mcg MK-7 daily. Higher doses (up to 360 mcg) used in some bone density studies. Take with fat-containing meal.
Side effects
- Very well tolerated
- No known toxicity
- Warfarin interaction is the primary concern
Who should be cautious
Contraindicated with warfarin and vitamin K antagonist anticoagulants. DOACs (rivaroxaban, apixaban) are less affected.
What this page cannot tell you
Cardiovascular calcification data is mostly observational. Large RCTs are ongoing. K1 and K2 have different primary functions.
Leaderboard scores
- Longevity60
Write a review
Sign in to write a review.